Editas Medicine (EDIT) Restructuring Costs (2024 - 2025)

Editas Medicine's (EDIT) quarterly Restructuring Costs came in at $26.1 million in Q2 2025, down 36.16% on a QoQ basis from $40.9 million in Q1 2025.

Editas Medicine (EDIT) Restructuring Costs (2024 - 2025) Analysis & Trends

Editas Medicine (EDIT) has 2 years of Restructuring Costs data on file, last reported at $26.1 million in Q2 2025.

On a quarterly basis, Restructuring Costs changed N/A year-over-year to $26.1 million in Q2 2025; TTM through Sep 2025 was $79.2 million, a N/A change from a year earlier, with the FY2024 full-year figure at $12.2 million, changed N/A from the prior year.
Restructuring Costs for Q2 2025 stood at $26.1 million, down from $40.9 million in the prior quarter.
Over the last five years, Restructuring Costs for EDIT reached as high as $40.9 million in Q1 2025 and fell as low as $12.2 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Editas Medicine	235.14 Mn	88.49 Mn	-

Download Data